---
title: "According to \"Blue Chip,\" CSPC PHARMA's net profit for the first three quarters is RMB 3.51 billion, a year-on-year decrease of 7.1%"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/266663234.md"
description: "CSPC PHARMA announced its performance for the first three quarters ending September this year, with a revenue of RMB 19.891 billion, a year-on-year decrease of 12.3%. The net profit was RMB 3.511 billion, a year-on-year decrease of 7.1%; earnings per share were 30.72 cents. R&D expenses increased by 7.9% to RMB 4.185 billion, accounting for 27.1% of the revenue from prescription drugs. The group has nearly 90 products in the clinical trial stage, 14 of which have submitted applications for listing, and over 30 key products are in the registration clinical stage"
datetime: "2025-11-20T04:04:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266663234.md)
  - [en](https://longbridge.com/en/news/266663234.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266663234.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/266663234.md) | [English](https://longbridge.com/en/news/266663234.md)


# According to "Blue Chip," CSPC PHARMA's net profit for the first three quarters is RMB 3.51 billion, a year-on-year decrease of 7.1%

CSPC PHARMA (01093.HK) announced its performance for the first three quarters ending September this year, with a revenue of RMB 19.891 billion, a year-on-year decrease of 12.3%. The net profit was RMB 3.511 billion, a year-on-year decrease of 7.1%; earnings per share were 30.72 cents.

Research and development expenses for this period increased by 7.9% compared to the same period last year to RMB 4.185 billion, accounting for approximately 27.1% of the revenue from the pharmaceutical business. Currently, there are nearly 90 products at different stages of clinical trials, of which 14 have submitted applications for market approval, and over 30 key products are in the registration clinical stage.

Since the beginning of the year, the group's registration and approval progress in China includes: 3 new products approved for market launch; 8 product applications accepted; 5 breakthrough therapy designations obtained; 42 clinical trial approvals received; and 9 generic drug registrations granted. In addition, the group obtained 10 clinical trial approvals for innovative drugs and 1 fast track designation in North America

### 相關股票

- [CSPC PHARMA (01093.HK)](https://longbridge.com/zh-HK/quote/01093.HK.md)

## 相關資訊與研究

- [CSPC Pharma's Profit Falls 10% in 2025; Misses EPS, Revenue Estimates](https://longbridge.com/zh-HK/news/280415449.md)
- [Tranche Update on CSPC Pharmaceutical Group Limited's Equity Buyback Plan announced on September 19, 2024.](https://longbridge.com/zh-HK/news/280502605.md)
- [CSPC Pharmaceutical, Alphamab Oncology's Breast Cancer Drug Study Meets Primary Endpoint](https://longbridge.com/zh-HK/news/281325910.md)
- [14:35 ETTowson University and Follett Higher Education announce the opening of reimagined UStore](https://longbridge.com/zh-HK/news/281229602.md)
- [09:35 ETHengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy](https://longbridge.com/zh-HK/news/281030940.md)